Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
View abstract on PubMed
Summary
This summary is machine-generated.Activators of the nuclear farnesoid X receptor (FXR) decrease Apolipoprotein CIII (Apo CIII) expression. This finding may explain how FXR agonists reduce triglyceride levels, a risk factor for coronary heart disease.
Area Of Science
- Metabolic regulation
- Molecular endocrinology
- Cardiovascular disease risk factors
Background
- Elevated serum triglyceride levels are a significant risk factor for coronary heart disease.
- Apolipoprotein CIII (Apo CIII) plays a key role in regulating serum triglyceride metabolism.
Purpose Of The Study
- To investigate whether activators of the nuclear farnesoid X receptor (FXR) influence Apo CIII gene expression.
- To explore the potential of FXR modulation for managing triglyceride levels.
Main Methods
- In vivo studies using FXR wild-type and deficient mice treated with bile acids or synthetic FXR agonists.
- In vitro studies with human primary hepatocytes and HepG2 cells.
- Gene expression analysis, promoter activity assays, and chromatin immunoprecipitation.
Main Results
- FXR activation by bile acids or synthetic agonists significantly reduced serum triglyceride levels in mice.
- Apo CIII gene expression and protein levels were down-regulated by FXR activators in both animal models and human cell lines.
- FXR directly binds to a negative response element in the Apo CIII promoter, leading to repression.
Conclusions
- Nuclear FXR activators, including bile acids and synthetic compounds, act as negative regulators of Apo CIII expression.
- This repression mechanism contributes to the triglyceride-lowering effects of FXR agonists.
- Targeting FXR may offer a therapeutic strategy for hypertriglyceridemia and associated cardiovascular risks.